GlassScriptPhysician profile
Melvin Wichter
NPI 1871503623
$15,528.84
in general payments reported to CMS, 2019-2025
55 companies · $3,372 in 2025
The $3,372 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $233 · 2021: $530 · 2022: $2,780 · 2023: $3,683 · 2024: $4,208 · 2025: $3,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,245.39 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,957.43 | 2019-2025 | Duopa, Qulipta, Botox |
| Biogen, INC. | $1,457.25 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Supernus Pharmaceuticals, INC. | $1,266.01 | 2019-2024 | Qelbree |
| Pfizer INC. | $923.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $794.34 | 2019-2025 | |
| Mdd US Operations, LLC | $765.54 | 2022-2025 | Apokyn |
| Ucb, INC. | $715.87 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Celgene Corporation | $707.62 | 2022-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $522.70 | 2019-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $407.30 | 2021-2024 | Zeposia |
| Emd Serono, INC. | $387.54 | 2019-2024 | Mavenclad |
| Catalyst Pharmaceuticals, INC. | $381.25 | 2023-2025 | Fycompa |
| Genentech USA, INC. | $380.91 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Lilly USA, LLC | $373.07 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Sk Life Science, INC. | $360.65 | 2022-2025 | Xcopri |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $338.48 | 2022-2025 | Hyqvia, Gammagard |
| Argenx US, INC. | $322.16 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Banner Life Sciences, LLC | $280.29 | 2022-2024 | |
| Eisai INC. | $262.13 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $212.12 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $212.08 | 2022 | |
| Jazz Pharmaceuticals INC. | $163.45 | 2020-2025 | Xywav |
| Neurocrine Biosciences, INC. | $159.76 | 2019-2021 | |
| Livanova USA, INC. | $154.96 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Janssen Pharmaceuticals, INC | $152.21 | 2022-2025 | Ponvory |
| Genzyme Corporation | $151.24 | 2019-2025 | |
| Acorda Therapeutics, INC | $149.19 | 2019-2023 | Inbrija, Ampyra |
| Alexion Pharmaceuticals, INC. | $136.64 | 2019-2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $115.67 | 2023-2025 | Nuedexta, Rexulti |
| Aucta Pharmaceuticals, INC. | $100.96 | 2024-2025 | Motpoly Xr |
| Abbott Laboratories | $97.59 | 2025 | Infinity |
| Amgen INC. | $97.35 | 2019-2024 | Uplizna |
| Impel Pharmaceuticals LLC | $92.59 | 2025 | Trudhesa |
| Vanda Pharmaceuticals INC. | $89.97 | 2024-2025 | Ponvory |
| Kyowa Kirin, INC. | $87.06 | 2022 | |
| Penumbra, INC. | $79.30 | 2021 | |
| Axsome Therapeutics, INC. | $66.63 | 2025 | Symbravo |
| Amneal Pharmaceuticals LLC | $63.53 | 2024-2025 | Rytary, Crexont |
| Neurelis, INC. | $49.67 | 2024-2025 | Valtoco |
| Mallinckrodt Hospital Products INC. | $47.94 | 2024-2025 | Acthar |
| Csl Behring | $47.53 | 2024 | Hizentra |
| Lundbeck LLC | $46.63 | 2023-2024 | Vyepti |
| Xeris Pharmaceuticals, INC. | $44.96 | 2023 | Keveyis |
| Akcea Therapeutics, INC. | $42.93 | 2019 | |
| Adamas Pharmaceuticals, INC. | $39.93 | 2019 | |
| Cala Health, INC. | $34.76 | 2022-2023 | Cala Trio |
| Harmony Biosciences LLC | $30.37 | 2023-2025 | Wakix |
| Sumitomo Pharma America, INC. | $28.49 | 2023 | Aptiom |
| Tg Therapeutics, INC. | $26.37 | 2025 | |
| Corium, LLC | $20.81 | 2023 | Adlarity |
| Janssen Biotech, INC. | $19.58 | 2025 | |
| Grifols USA, LLC | $18.73 | 2024 | Gamunex-C |
| Cycle Pharmaceuticals INC | $17.73 | 2025 | Bafiertam |
| Genentech, INC. | $13.45 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Wichter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.